Form 8-K - Current report:
SEC Accession No. 0001628280-25-004254
Filing Date
2025-02-06
Accepted
2025-02-06 16:06:22
Documents
15
Period of Report
2025-02-06
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K xfor-20250206.htm   iXBRL 8-K 35725
2 EX-99.1 exhibit991feb62025.htm EX-99.1 14867
6 image_0.jpg GRAPHIC 12851
  Complete submission text file 0001628280-25-004254.txt   205599

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20250206.xsd EX-101.SCH 1785
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20250206_lab.xml EX-101.LAB 23449
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20250206_pre.xml EX-101.PRE 13583
17 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20250206_htm.xml XML 2824
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 25597379
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)